argenx SE - American Depositary Shares (ARGX) Covered Calls
You can sell covered calls on argenx SE - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ARGX (prices last updated Wed 1:15 PM ET):
argenx SE - American Depositary Shares (ARGX) Stock Quote | ||||||
---|---|---|---|---|---|---|
Last | Change | Bid | Ask | Volume | P/E | Market Cap |
585.38 | +10.84 | 585.21 | 587.07 | 215K | - | 0.0 |
Covered Calls For argenx SE - American Depositary Shares (ARGX) | ||||||
---|---|---|---|---|---|---|
Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
Dec 20 | 590 | 16.00 | 571.07 | 2.8% | 33.0% | |
Jan 17 | 590 | 29.00 | 558.07 | 5.2% | 32.2% | |
Subscribers get access to the full covered call chain, and more features. |
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
---|---|---|---|---|---|---|
1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
2. | SPY covered calls | 7. | XLF covered calls | 2. | CRVS covered calls | |
3. | EEM covered calls | 8. | TLT covered calls | 3. | CLSK covered calls | |
4. | FXI covered calls | 9. | KWEB covered calls | 4. | APLT covered calls | |
5. | IWM covered calls | 10. | AAPL covered calls | 5. | ANAB covered calls |
Want more examples? ARGT Covered Calls | ARI Covered Calls